CRX 675Alternative Names: CRX-675
Latest Information Update: 25 May 2007
At a glance
- Originator GlaxoSmithKline
- Class Antiallergics
- Mechanism of Action Toll-like receptor 4 agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Seasonal allergic rhinitis